Transgenic Group Second Quarter 2025 Earnings: JP¥4.99 loss per share (vs JP¥1.78 loss in 2Q 2024)
Transgenic Group (TSE:2342) Second Quarter 2025 Results
Key Financial Results
- Revenue: JP¥3.43b (up 11% from 2Q 2024).
- Net loss: JP¥83.0m (loss widened by 177% from 2Q 2024).
- JP¥4.99 loss per share (further deteriorated from JP¥1.78 loss in 2Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Transgenic Group shares are down 11% from a week ago.
Risk Analysis
Don't forget that there may still be risks. For instance, we've identified 2 warning signs for Transgenic Group (1 is a bit concerning) you should be aware of.
Valuation is complex, but we're here to simplify it.
Discover if Transgenic Group might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TSE:2342
Transgenic Group
Develops, distributes, and licenses genetically modified animals and antibodies in Japan.
Mediocre balance sheet and slightly overvalued.
